Medicines in this atlas
The drugs and medicine products this atlas holds that a registry trial names or that carry a regulatory decision, with how many of each. A trial counts for a medicine when its registry record names the medicine under a name this atlas holds for it, so the table does not list every medicine used in these conditions. (page 1 of 4)
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Drug
- Class
- Trials
- 1
- Phase 3 or 4
- 1
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 1
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Drug
- Class
- PCSK9 inhibitors
- Trials
- 28
- Phase 3 or 4
- 25
- Recruiting
- 1
- Regulatory decisions
- 0
- Sponsors
- 7
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 3
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Drug
- Class
- Fibrinolytic (clot-dissolving) drugs
- Trials
- 14
- Phase 3 or 4
- 12
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 10
-
- Type
- Drug
- Class
- Antiarrhythmic drugs
- Trials
- 20
- Phase 3 or 4
- 19
- Recruiting
- 3
- Regulatory decisions
- 0
- Sponsors
- 20
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Drug
- Class
- Calcium channel blockers
- Trials
- 40
- Phase 3 or 4
- 30
- Recruiting
- 5
- Regulatory decisions
- 0
- Sponsors
- 30
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 3
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
Angiotensin receptor blockers (ARBs)
- Type
- Drug
- Class
- Trials
- 14
- Phase 3 or 4
- 11
- Recruiting
- 3
- Regulatory decisions
- 0
- Sponsors
- 14
-
- Type
- Drug
- Class
- Trials
- 23
- Phase 3 or 4
- 22
- Recruiting
- 2
- Regulatory decisions
- 0
- Sponsors
- 21
-
- Type
- Drug
- Class
- Trials
- 1
- Phase 3 or 4
- 1
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 1
-
- Type
- Drug
- Class
- Trials
- 47
- Phase 3 or 4
- 39
- Recruiting
- 12
- Regulatory decisions
- 0
- Sponsors
- 36
-
- Type
- Product
- Class
- Trials
- 2
- Phase 3 or 4
- 2
- Recruiting
- 0
- Regulatory decisions
- 5
- Sponsors
- 2
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 6
- Sponsors
- 0
-
- Type
- Drug
- Class
- Trials
- 116
- Phase 3 or 4
- 97
- Recruiting
- 25
- Regulatory decisions
- 0
- Sponsors
- 97
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 5
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Drug
- Class
- Beta-blockers (drug class)
- Trials
- 5
- Phase 3 or 4
- 4
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 5
-
- Type
- Drug
- Class
- Statins
- Trials
- 81
- Phase 3 or 4
- 64
- Recruiting
- 7
- Regulatory decisions
- 0
- Sponsors
- 57
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 2
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 2
- Sponsors
- 0
-
- Type
- Drug
- Class
- Trials
- 12
- Phase 3 or 4
- 11
- Recruiting
- 3
- Regulatory decisions
- 0
- Sponsors
- 6
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 2
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Drug
- Class
- Trials
- 28
- Phase 3 or 4
- 24
- Recruiting
- 3
- Regulatory decisions
- 0
- Sponsors
- 22
-
- Type
- Drug
- Class
- Beta-blockers (drug class)
- Trials
- 15
- Phase 3 or 4
- 13
- Recruiting
- 1
- Regulatory decisions
- 0
- Sponsors
- 12
-
- Type
- Drug
- Class
- Anticoagulants
- Trials
- 13
- Phase 3 or 4
- 13
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 11
BIVALIRUDIN IN 0.9% SODIUM CHLORIDE
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 7
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 2
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 3
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 2
- Sponsors
- 0
-
- Type
- Drug
- Class
- Trials
- 11
- Phase 3 or 4
- 10
- Recruiting
- 1
- Regulatory decisions
- 0
- Sponsors
- 9
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 4
- Sponsors
- 0
-
- Type
- Drug
- Class
- Angiotensin receptor blockers (ARBs)
- Trials
- 8
- Phase 3 or 4
- 5
- Recruiting
- 1
- Regulatory decisions
- 0
- Sponsors
- 8
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 2
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 4
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 3
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 2
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Drug
- Class
- Beta-blockers (drug class)
- Trials
- 10
- Phase 3 or 4
- 10
- Recruiting
- 3
- Regulatory decisions
- 0
- Sponsors
- 10
-
- Type
- Drug
- Class
- Thiazide and thiazide-like diuretics
- Trials
- 5
- Phase 3 or 4
- 4
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 5
-
- Type
- Drug
- Class
- P2Y12 inhibitors (drug class)
- Trials
- 109
- Phase 3 or 4
- 91
- Recruiting
- 11
- Regulatory decisions
- 0
- Sponsors
- 89
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Drug
- Class
- Trials
- 46
- Phase 3 or 4
- 37
- Recruiting
- 9
- Regulatory decisions
- 0
- Sponsors
- 35
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 2
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 7
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 5
- Sponsors
- 0
-
- Type
- Drug
- Class
- Trials
- 13
- Phase 3 or 4
- 12
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 13
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 4
- Sponsors
- 0
-
- Type
- Drug
- Class
- SGLT2 inhibitors (drug class)
- Trials
- 92
- Phase 3 or 4
- 82
- Recruiting
- 17
- Regulatory decisions
- 0
- Sponsors
- 54
-
- Type
- Product
- Class
- Trials
- 5
- Phase 3 or 4
- 5
- Recruiting
- 1
- Regulatory decisions
- 9
- Sponsors
- 4
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 2
- Sponsors
- 0
-
- Type
- Drug
- Class
- Calcium channel blockers
- Trials
- 6
- Phase 3 or 4
- 5
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 6
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
DILTIAZEM HYDROCHLORIDE IN DEXTROSE 5%
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 2
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 6
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 4
- Sponsors
- 0
Direct oral anticoagulants (DOACs)
- Type
- Drug
- Class
- Anticoagulants
- Trials
- 1
- Phase 3 or 4
- 1
- Recruiting
- 1
- Regulatory decisions
- 0
- Sponsors
- 1
-
- Type
- Drug
- Class
- Inotropes and vasopressors
- Trials
- 4
- Phase 3 or 4
- 3
- Recruiting
- 1
- Regulatory decisions
- 0
- Sponsors
- 3
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 2
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Drug
- Class
- Trials
- 18
- Phase 3 or 4
- 14
- Recruiting
- 1
- Regulatory decisions
- 0
- Sponsors
- 13
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 3
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Drug
- Class
- SGLT2 inhibitors (drug class)
- Trials
- 67
- Phase 3 or 4
- 54
- Recruiting
- 15
- Regulatory decisions
- 0
- Sponsors
- 39
-
- Type
- Product
- Class
- Trials
- 1
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 10
- Sponsors
- 1
-
- Type
- Drug
- Class
- ACE inhibitors
- Trials
- 15
- Phase 3 or 4
- 13
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 7
-
- Type
- Drug
- Class
- Trials
- 16
- Phase 3 or 4
- 10
- Recruiting
- 1
- Regulatory decisions
- 0
- Sponsors
- 15